Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
13.96
+0.09 (0.65%)
Sep 17, 2025, 12:00 PM EDT - Market open
Theravance Biopharma Revenue
Theravance Biopharma had revenue of $26.20M in the quarter ending June 30, 2025, with 83.75% growth. This brings the company's revenue in the last twelve months to $77.21M, up 24.49% year-over-year. In the year 2024, Theravance Biopharma had annual revenue of $64.38M with 12.12% growth.
Revenue (ttm)
$77.21M
Revenue Growth
+24.49%
P/S Ratio
8.90
Revenue / Employee
$795,928
Employees
97
Market Cap
703.04M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 64.38M | 6.96M | 12.12% |
Dec 31, 2023 | 57.42M | 6.08M | 11.84% |
Dec 31, 2022 | 51.35M | -3.97M | -7.17% |
Dec 31, 2021 | 55.31M | -16.55M | -23.03% |
Dec 31, 2020 | 71.86M | -1.56M | -2.12% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
TBPH News
- 15 days ago - Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference - PRNewsWire
- 23 days ago - Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy - PRNewsWire
- 5 weeks ago - Theravance Biopharma, Inc. (TBPH) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 7 weeks ago - Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025 - PRNewsWire
- 2 months ago - Theravance Biopharma to Participate in an Upcoming Investor Conference - PRNewsWire
- 2 months ago - Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA - PRNewsWire
- 3 months ago - Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million - PRNewsWire